News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,862 Results
Type
Article (41878)
Company Profile (473)
Press Release (663511)
Section
Business (208545)
Career Advice (2039)
Deals (35982)
Drug Delivery (97)
Drug Development (83452)
Employer Resources (169)
FDA (16365)
Job Trends (15065)
News (352447)
Policy (33023)
Tag
Academia (2622)
Alliances (50809)
Alzheimer's disease (1336)
Approvals (16319)
Artificial intelligence (172)
Bankruptcy (363)
Best Places to Work (11814)
Biotechnology (355)
Breast cancer (210)
Cancer (1574)
Cardiovascular disease (130)
Career advice (1697)
CAR-T (111)
Cell therapy (332)
Clinical research (66741)
Collaboration (600)
Compensation (312)
COVID-19 (2613)
C-suite (140)
Data (1497)
Diabetes (193)
Diagnostics (6262)
Earnings (86263)
Employer resources (147)
Events (113892)
Executive appointments (494)
FDA (17158)
Funding (538)
Gene therapy (235)
GLP-1 (658)
Government (4428)
Healthcare (19078)
Infectious disease (2710)
Inflammatory bowel disease (121)
Interviews (318)
IPO (16676)
Job creations (3698)
Job search strategy (1445)
Layoffs (451)
Legal (7952)
Lung cancer (230)
Manufacturing (222)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19560)
Metabolic disorders (521)
Neuroscience (1725)
NextGen: Class of 2025 (6750)
Non-profit (4542)
Northern California (1893)
Obesity (297)
Opinion (206)
Patents (134)
People (58023)
Phase I (20956)
Phase II (29458)
Phase III (21769)
Pipeline (626)
Postmarket research (2599)
Preclinical (8953)
Radiopharmaceuticals (255)
Rare diseases (305)
Real estate (6003)
Regulatory (22255)
Research institute (2410)
Resumes & cover letters (353)
Southern California (1647)
Startups (3754)
United States (17127)
Vaccines (596)
Weight loss (211)
Date
Today (140)
Last 7 days (419)
Last 30 days (2006)
Last 365 days (35950)
2025 (1787)
2024 (36353)
2023 (41026)
2022 (52288)
2021 (56776)
2020 (54947)
2019 (47441)
2018 (35721)
2017 (33042)
2016 (32369)
2015 (38413)
2014 (32206)
2013 (27123)
2012 (29238)
2011 (29877)
2010 (28003)
Location
Africa (733)
Arizona (211)
Asia (38833)
Australia (6451)
California (4358)
Canada (1567)
China (370)
Colorado (194)
Connecticut (217)
Europe (84682)
Florida (609)
Georgia (147)
Illinois (430)
Indiana (245)
Maryland (705)
Massachusetts (3425)
Michigan (185)
Minnesota (323)
New Jersey (1208)
New York (1222)
North Carolina (848)
Northern California (1893)
Ohio (156)
Pennsylvania (1012)
South America (1110)
Southern California (1647)
Texas (635)
Utah (122)
Washington State (443)
705,862 Results for "an2 therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
AN2 Therapeutics Laying Off Half Its Workforce
AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.
August 9, 2024
·
1 min read
·
Angela Gabriel
Press Releases
AN2 Therapeutics to Participate at Upcoming Investor Conferences
November 14, 2024
·
1 min read
Business
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.
May 14, 2024
·
8 min read
Biotech Bay
AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference
AN2 Therapeutics, Inc. (Nasdaq: ANTX) today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
January 30, 2024
·
1 min read
Business
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.
March 28, 2024
·
10 min read
Press Releases
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria
October 18, 2024
·
4 min read
Press Releases
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
November 14, 2024
·
12 min read
Biotech Bay
AN2 Therapeutics to Present at Upcoming November 2023 Investor Conferences
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced that company management will participate in two upcoming investor conferences in November.
November 6, 2023
·
1 min read
Biotech Bay
AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023
AN2 Therapeutics, Inc. announced two oral presentations and three poster presentations at the Infectious Disease Society of America IDWeek 2023 Conference from October 11-15, 2023 in Boston, Massachusetts.
October 11, 2023
·
5 min read
Business
AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended September 30, 2023.
November 9, 2023
·
9 min read
1 of 70,587
Next
